Research Funded by Curebound Gains Continued Momentum with Follow-On Funding for Cancer Research Clinical Trials and Scientific Accolades for New AI Precision-Oncology Platform

Philanthropic organization that raises and invests funding in pioneering cancer research announces two of its grant recipients – one studying fertility in cancer patients and another, studying pancreatic cancer – have received support to expand clinical trials, with another grant recipient recognized for generational advance in AI

SAN DIEGO: #cancer--Curebound, a philanthropic organization that raises and invests strategic funding for cancer research, is announcing important updates on its grant recipients. This includes $4.1M in follow-on funding recently obtained by its 2021 oncofertility Discovery Grant recipient to expand clinical trials; an additional $1.2M secured by one of its 2023 Cure Prize recipients to further support and expand clinical trials in pancreatic cancer research; and recognition for one of its 2023 Targeted Grant recipients on its new, transformational Artificial Intelligence (AI) precision-oncology platform.

In particular:

• Curebound 2021 Discovery Grant recipients H. Irene Su, MD, MSCE, University of California, San Diego, and Paula Aristizabal, MD, MAS, Rady Children’s Hospital, have received $4.1M in follow-on funding to expand clinical trials for their Oncofertility Care Program. The additional funding will allow the program, aimed at preserving fertility for cancer patients, to expand to 19 clinics across three Southern California health systems.